MedPath

System Accuracy and User Performance of Blood Glucose Monitoring Systems for Self-Testing in Managing Diabetes Mellitus

Not Applicable
Completed
Conditions
Diabetes
Interventions
Device: Blood glucose monitoring system (Omnitest 5D)
Device: Blood glucose monitoring system (Omnitest 3)
Device: Blood glucose monitoring system (Omnitest 5)
Registration Number
NCT02290067
Lead Sponsor
B. Braun Melsungen AG
Brief Summary

The aim of this test is to determine the system accuracy and user performance evaluation of three Blood Glucose Monitoring systems. For system accuracy evaluation the measurement data should cover the whole range of glucose concentration which could usually be expected in patients with diabetes mellitus.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
130
Inclusion Criteria
  • Subjects with type 1 or type 2 diabetes and healthy subjects
  • Signed and dated informed consent form
  • For small modifications of the insulin doses to achieve certain blood glucose values (system accuracy evaluation): Male or female subjects with diabetes mellitus type 1 with intensified insulin therapy (intensified conventional therapy) or insulin pump therapy (continuous subcutaneous insulin infusion)
Exclusion Criteria
  • Pregnancy or lactation period
  • Severe acute illness that in the opinion of the investigating physician might confound the results of the test or which could result in a risk to the patient caused by the test
  • Mental incapacity or language barriers precluding adequate compliance with the test procedures
  • Severe chronic illness besides diabetes mellitus as assessed by the investigating physician that might confound the results of the test or which could result in a risk to the patient caused by the test
  • Legal incompetence or limited legal competence
  • Dependency from the sponsor or the clinical investigator (e.g. coworkers of the sponsor or the clinical research center)
  • For user performance evaluation: Subjects having used the test systems before themselves or having participated in a study with these Blood Glucose Monitoring Systems
  • For system accuracy evaluation: subjects intended to provide blood samples with glucose concentrations between 50 and 80 mg/dl must not have coronary heart disease, myocardial infarction in history, cerebral events in history, peripheral artery occlusive disease- or impaired hypoglycaemia awareness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Omnitest 5DBlood glucose monitoring system (Omnitest 5D)Blood glucose monitoring system
Omnitest 3Blood glucose monitoring system (Omnitest 3)Blood glucose monitoring system
Omnitest 5Blood glucose monitoring system (Omnitest 5)Blood glucose monitoring system
Primary Outcome Measures
NameTimeMethod
User performance of blood glucose monitoring systems indicated by patient [questionnaire]up to 4 hours
System accuracy, results obtained from fingertip using blood glucose monitoring systems compared to a reference equipmentup to 6 hours
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft

🇩🇪

ULM, Germany

© Copyright 2025. All Rights Reserved by MedPath